Early studies in CAR T-cell therapy identified that cytokine blockade with tocilizumab, an anti-interleukin (IL)-6 receptor (IL-6R) monoclonal antibody, was highly effective at treating CRS without compromising efficacy, leading to FDA approval of tocilizumab for this indication (11, 16, 27). Here, IL6R is linked to congenital rubella syndrome.